- Keytruda — Merck’s Keytruda has been approved to treat triple-negative breast cancer in combination with chemotherapy. The drug has now been approved to treat 30 types of cancer.
- Bydureon — AstraZeneca’s Bydureon has been approved to treat Type 2 diabetes in pediatric patients ages 10 years and older.
- Rezurock — Kadmon Pharmaceuticals’ Rezurock has been approved to treat chronic graft-versus-host disease.
- Wegovy — Novo Nordisk’s Wegovy has been approved to treat obesity, the first new drug to treat the condition approved by the FDA in seven years.
- Rylaze — Jazz Pharmaceuticals’ Rylaze has been approved as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the drugs used most commonly for treatment.
- Pradaxa — Boehringer Ingelheim’s Pradaxa has been approved to treat venous thromboembolism, a condition where blood clots form in the veins, in children 3 months to under 12 years old. It is the first FDA-approved blood-thinning medication that children can take by mouth.
- Astepro — Bayer’s Astepro, a nasal antihistamine, has been approved for nonprescription use. Astepro is approved to treat seasonal and perennial allergic rhinitis in adults and children over 6 years.
